Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Novavax's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $14.2 Mil. Novavax's Average Total Inventories for the quarter that ended in Jun. 2026 was $10.7 Mil.
Novavax's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.33.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Novavax's Days Inventory for the
three
months ended in Jun. 2026 was 68.74.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novavax's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.19.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Novavax's Days Inventory for the
three
months ended in Jun. 2026 is calculated as:
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novavax's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Novavax Inventory Turnover Related Terms
Novavax Inventory Turnover Historical Data
* Premium members only.
The historical data trend for Novavax's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax (NVAX) has a Inventory Turnover of 1.33 as of Jun. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Novavax and its competitors.
Is Novavax's Inventory Turnover too high?
Novavax's current Inventory Turnover is 1.33. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Inventory Turnover compare to JBIO and AVLN?
Novavax's Inventory Turnover of 1.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Novavax and its competitors. Novavax's current Inventory Turnover is 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.26, compared to a current price of $7.89 — trading 141.9% above its estimated fair value. The current Inventory Turnover is 1.33. Novavax's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Novavax (NVAX), the current Inventory Turnover is 1.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of $7.89 is trading 141.9% above its estimated GF Value™ of $3.26.
GuruFocus considers Novavax to be Significantly Overvalued.
Key valuation signals for NVAX:
Inventory Turnover: 1.33
GF Value™: $3.26 vs. price of $7.89 (141.9% above fair value)
No single metric tells the full story. See the NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score
Get the complete analysis for NVAX
Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVAX has been successfully added to your 
